Anti-HER2 therapy in metastatic breast cancer: many choices and future directions

Area of Science:

• Oncology
• Medical Research
• Drug Development

Background:

• Metastatic HER2-positive breast cancer treatment is evolving, with new drug approvals and shifting standards of care.
• Trastuzumab resistance, often due to p95 HER2 expression, presents a challenge in third-line therapy.
• Brain metastases are a significant concern in managing advanced HER2-positive breast cancer.

Purpose of the Study:

• To review current and emerging treatment strategies for metastatic HER2-positive breast cancer.
• To explore the role of tyrosine kinase inhibitors (TKIs) in overcoming resistance and treating brain metastases.
• To discuss future directions, including novel mechanisms of action and predictive biomarkers.

Main Methods:

• Review of recent clinical trial data, focusing on the DESTINY-Breast03 trial.
• Analysis of resistance mechanisms, including p95 HER2 expression.
• Evaluation of TKI efficacy in preclinical and clinical settings.

Main Results:

• The DESTINY-Breast03 trial is expected to influence second-line therapy standards.
• Tyrosine kinase inhibitors demonstrate activity against brain metastases and p95 HER2-expressing tumors.
• Ongoing research focuses on PI3K, mTOR, and CDK 4/6 inhibitors to overcome resistance.

Conclusions:

• TKI-based regimens are a promising option for third-line treatment of metastatic HER2-positive breast cancer.
• Further research is needed to identify biomarkers for personalized therapy selection.
• Novel therapeutic approaches and drugs are under active investigation.